Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 9NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 3Tumor-Agnostic 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Neoplasm Metastasis 1

Interventions

regorafenib 2Radiotherapy 2Music Therapy 2Interviews as Topic 2Albumin-Bound Paclitaxel 2trifluridine tipiracil drug combination 1tremelimumab 1plozalizumab 1pegfilgrastim 1nintedanib 1merphos 1durvalumab 1cabozantinib 1Vinblastine 1Trifluridine 1Surveys and Questionnaires 1Standard of Care 1Spermine Synthase 1Radiosurgery 1Psychiatrists 1Psychiatric Rehabilitation 1Proton Therapy 1Prednisone 1Practice Guidelines as Topic 1Platinum 1Paclitaxel 1Oxycodone 1Oxaliplatin 1Olanzapine 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Practice Guidelines as Topic × Tumor-Agnostic × Clear all
NCT05455606 2026-01-22

Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment

SWOG Cancer Research Network

Phase NA Active not recruiting
1,284 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡